Amsterdam-based EvidenceHunt, an AI-powered medical research platform, announced that it has secured €1.2M in a funding round led by Keen Venture Partners, Dff.ventures, and Slimmer AI.
The consortium was joined by notable angel investors, including Jeroen Tas (former Chief Strategy and Innovation Officer at Philips), Dinko Valerio (former CEO and Founder Crucell), and James Shannon (former Head of Global Drug Development Novartis).
EvidenceHunt is using funding to improve its platform for processing medical information.
What does EvidenceHunt solve?
Searching for medical evidence is often time-consuming and frustrating.
Professionals spend many hours searching through PubMed, guidelines, and protocols for reliable answers.
This inefficiency wastes time and slows down evidence-based decision-making.
Here is where EvidenceHunt comes into play!
“As a medical doctor and PhD, I know firsthand how frustrating it can be to spend countless hours navigating PubMed, guidelines, and protocols. From day one, we built EvidenceHunt to mimic domain-specific logic and processes for evaluating and interpreting literature. But we aim to do more than just save time – we provide clear answers that users can trace back to credible sources,” says Philippe Habets, CEO of EvidenceHunt.
EvidenceHunt: Streamlining research
Led by Philippe Habets, EvidenceHunt transforms how professionals pinpoint, analyse and process medical evidence.
With this platform, users can now ask questions and receive clear, summarised answers within seconds – complete with cited sources and trackable details for instant verification of how the AI
has generated its answers.
“Unlike generic AI platforms, our goal with EvidenceHunt is not to be a black box; it’s designed to empower users with transparency and reliability, which are essential for adoption and for earning the trust of the medical community,” adds Habets.
Focusing on specific topics and extracting precise data from large amounts of literature – like searching for a needle in a haystack – can now be done quickly, claims the company.
As a result, literature reviews, which previously took several days or even weeks, can now be completed in a matter of hours.
Depending on their profession and use cases, users have reported saving up to 5 hours per week.
Teams will have full control over the input, deciding what type of data they integrate, such as protocols, guidelines, unpublished research, or any other internal document.
At the same time, they gain control over the output.
Instead of just receiving summaries, they can build structured dossiers, documentation, or templates directly within EvidenceHunt.
Additionally, the platform offers advanced collaboration features, allowing healthcare and pharmaceutical professionals to find and share relevant information more quickly and effectively.
Since its inception, the company has grown organically to a global userbase of 25,000 active and returning users, including healthcare professionals, medical science experts, researchers and students across 90+ countries.
01
Upstream Festival is back for its sixth edition! 4 solid reasons to mark your calendar